ArticleInternational journal of clinical and experimental pathology2014
Long noncoding RNA GHET1 promotes the development of bladder cancer.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Prognostic significance of LncRNA GHET1 expression in various cancers: a systematic review and meta-analysis.Bioscience reports · 2019Pooled it
- Overexpression of LncRNA GHET1 predicts an unfavourable survival and clinical parameters of patients in various cancers.Journal of cellular and molecular medicine · 2019Pooled it
- Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism.Non-coding RNA research · 2024Review
- Long non-coding RNAs: regulators of autophagy and potential biomarkers in therapy resistance and urological cancers.Frontiers in pharmacology · 2024Review
- Epigenetic and Immunological Features of Bladder Cancer.International journal of molecular sciences · 2023Review
- Long non-coding RNA GHET1 promotes thyroid cancer cell proliferation and invasion.Translational cancer research · 2021Article
- Review
- Knockdown of long non-coding RNA GHET1 suppresses cervical carcinoma in vitro and in vivo.Cancer biomarkers : section A of Disease markers · 2020Article
- Prognostic value of long non-coding RNA GHET1 in cancers: a systematic review and meta-analysis.Cancer cell international · 2020Review
- Long non-coding RNA GHET1/miR-105/RAP2B axis regulates the progression of acute myeloid leukemia.Journal of Cancer · 2020Article
- Clinicopathological and Prognostic Value of Gastric Carcinoma Highly Expressed Transcript 1 in Cancer: A Meta-Analysis.Journal of oncology · 2020Article
- Long non-coding RNA RNCR3 promotes glioma progression involving the Akt/GSK-3β pathway.Oncology letters · 2019Article
- Article
- Long non-coding RNAs in genitourinary malignancies: a whole new world.Nature reviews. Urology · 2019Review
- Long non-coding RNA GEHT1 promoted the proliferation of ovarian cancer cells via modulating the protein stability of HIF1α.Bioscience reports · 2019Article
- GHET1 acts as a prognostic indicator and functions as an oncogenic lncRNA in cervical cancer.Bioscience reports · 2019Article
- Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer.International journal of molecular sciences · 2019Review
- High Apelin Level Indicates a Poor Prognostic Factor in Muscle-Invasive Bladder Cancer.Disease markers · 2019Article
- lncRNA GHET1 knockdown suppresses breast cancer activity in vitro and in vivo.American journal of translational research · 2019Article
- Downregulated Long Noncoding RNA PART1 Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer.Technology in cancer research & treatment · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In spite of the advances in the diagnosis and treatment of bladder cancer, the prognosis of bladder cancer remains relatively poor. As a result, it is vital to identify novel diagnostic and prognostic marker of bladder cancer. A growing volume of literature has implicated the vital role of long noncoding RNA in the development of cancer. GHET1, a recently identified lncRNA, was initially characterized in gastric cancer. However, its role in bladder cancer remains largely unknown. In this study, we demonstrated that GHET1 was upregulated in bladder cancer tissues compared to adjacent normal tissues and its over-expression correlates with tumor size, advanced tumor and lymph node status, and poor survival. GHET1 knockdown suppressed the proliferation and invasion of bladder cancer cells in vitro. In the meantime, inhibition of GHET1 reversed the epithelial-mesenchymal-transition in bladder cancer cell line. Taken together, our study suggests that the potential use of GHET1 as a prognostic marker and therapeutic target of bladder cancer.
Indexed as
Identifiers
25400817PMC4230137W2395677963What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.